No effect of n-3 fatty acids supplementation on NT-proBNP after myocardial infarction: The Alpha Omega Trial. (29th August 2020)

• Record Type: Journal Article
• Authors: Hoogeveen, Ellen K; Geleijnse, Johanna M; Kromhout, Daan; van't Sant, Peter; Gemen, Eugenie F; Kusters, Ron; Giltay, Erik J
• Is Part Of: European journal of preventive cardiology. Volume 22:Number 5(2015)
• Page Start: 648
• Page End: 655
• Publication Date: 2020-08-29
• Subjects: n-3 Polyunsaturated fatty acids -- alpha-linolenic acid -- eicosapentaenoic acid -- docosahexaenoic acid -- NT-proBNP -- randomized double-blind placebo-controlled trial; Cardiovascular system -- Diseases -- Prevention -- Periodicals; Cardiac patients -- Rehabilitation -- Periodicals; 616.12
• DOI: 10.1177/2047487314536694
• Languages: English
• ISSNs: 2047-4873

Abstract

Abstract: Background: heart failure is a major risk factor for cardiovascular mortality, for which n-3 fatty acids may have beneficial effects. We examined the effect of marine eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and plant-derived alpha-linolenic acid (ALA) on N-Terminal-pro Brain Natriuretic Peptide (NT-proBNP), a biomarker of heart failure. Methods: we randomly assigned 4837 post-myocardial infarction patients, aged 60–80 years (82% men), to margarines supplemented with a targeted additional intake of 400 mg/day EPA and DHA, 2 g/day ALA, EPA-DHA plus ALA, or placebo for 40 months. In a random selection of 639 patients, NT-proBNP was determined both at baseline and at the end of follow-up. NT-proBNP was loge -transformed and analysed by type of treatment using analysis of covariance adjusting for baseline NT-proNBP. Results: patients consumed on average 19.8 g margarine/day, providing an additional amount of 238 mg/day EPA with 158 mg/day DHA, 1.98 g/day ALA, or both, in the active-treatment groups. In the placebo group, the geometric mean level NT-proBNP increased from 245 ng/l (95%-confidence interval [CI]: 207–290) to 294 ng/l (95%-CI: 244–352) after 40 months ( p = 0.001). NT-proBNP levels were not affected by ALA (+8% versus placebo; 95%-CI: −8% to +25%; p = 0.34), EPA-DHA (+2% versus placebo; 95%-CI: −14% to +18%; p = 0.78), nor EPA-DHA plus ALA (+9% versus placebo; 95%-CI: −8% to +25%; p = 0.31) treatment. Conclusions: supplementation with modest amounts of EPA-DHA, with or without ALA, did not have a significant effect on NT-proBNP levels in patients with a history of myocardial infarction.